BOSTON, June 9, 2015 /PRNewswire/ -- OpenClinica announced today the availability of Participate, a mobile, device independent solution for engaging participants in clinical research. Participate broadens possibilities for clinical research, by making it easier to meaningfully engage patients and collect high quality, timely data from patients in a way that is convenient for them.
To date, OpenClinica has been known for its clinical trial electronic data capture software, widely used by biopharma, medical device, CRO, and academic researchers. The addition of Participate adds a friendly and effective way to engage patients directly in those same OpenClinica-powered clinical studies.
"Collecting accurate, timely, useful data directly from patients has been a longstanding challenge for clinical research," said OpenClinica's Alicia Goodwin, who helped design Participate. "Researchers have either relied on antiquated paper diaries or the provisioning of additional devices to patients, both of which are expensive, logistically complex, and unreliable. Participate makes it easy to create and send forms directly to study participants in a simple and secure interface on their own smartphone, tablet, or PC. With the state of technology today, we believe there is no longer a need to use paper PROs alongside EDC, or engage multiple specialized vendors resulting in siloed data sets and integration complexity."
Using Participate with OpenClinica EDC allows researchers to design participant-facing events, reminders, and assessments alongside clinical visits and CRFs, using OpenClinica's existing, user-friendly study build tools. All the clinical and patient reported outcomes data are seamlessly captured in a single place. As data are submitted by study participants, their activities become part of the same regulatory compliant audit trail that tracks all clinical user activity. The data participants submit, are immediately available for review and analysis alongside CRF data from other sources.
"The difficulty of engaging with study volunteers in a meaningful and timely way is as an obstacle to successful research. We live in a world where 90% of adults have smartphones, 81% text, and 63% use their phone to go online. We need to reach patients on their terms, whether email, SMS, web, or a mobile device," said Cal Collins, OpenClinica's CEO. "Treating research volunteers as participants, as opposed to subjects, can lead to concrete benefits, such as improved compliance more effective recruiting, and more complete, timely data. It can even help enable new protocol designs that better target populations and/or more closely align with real-world use. But most of all, it just seems like the right thing to do."
OpenClinica Participate will be showcased at the upcoming OpenClinica Global Conference, May 31-June 1 inAmsterdam and DIA 2015 (Booth 635) in Washington DC, June 14-18.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.